Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based novel drug developer Isis Pharmaceuticals has received a payment of $6m from AstraZeneca to continue their contract research agreement to discover and develop new antisense therapeutics to treat cancer.
Subscribe to our email newsletter
Besides collaborating on three cancer targets, AstraZeneca is also developing two antisense drugs, ISIS-AR and ISIS-STAT3 discovered by Isis. AstraZeneca had acquired license for the two antisense drugs from Isis.
Commenting on the research partnership, Isis Pharmaceuticals chief operating officer Lynne Parshall said, "Our oncology franchise consists of five antisense drugs in development to treat patients with a variety of cancers."
Isis entered into an agreement with AstraZeneca in December 2012 to discover and develop antisense drugs in treating cancer.
In upfront and milestone payments from AstraZeneca, Isis has earned $41m, including the $6m payment, and is eligible to earn additional milestone payments as the agreement progresses.